KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., incorporated on March 26, 2004, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies.
The Company is developing oral plasma kallikrein inhibitors for the prophylactic treatment of HAE. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial in healthy volunteers to evaluate the safety of single and multiple ascending doses. The Company is engaged in developing multiple formulations of KVD818. The Company focuses on advancing various formulations of KVD818, as well as additional oral kallikrein inhibitors, into Phase I clinical trials.
The Company has completed an open-label single ascending dose Phase I trial in DME patients with KVD001. The Company's product candidate, KVD001, is an inhibitor of human plasma kallikrein. It is selective against a range of proteases, including closely related proteases, such as tissue kallikrein.
227 Bldg, Tetricus Science Park
The company trades on NASDAQ exchange. The company headquarter is located in United Kingdom.| Ticker | KALV |
| Long Name | KalVista Pharmaceuticals, Inc. |
| Short Name | KalVista Pharma |